Literature DB >> 22365253

Smoking-related interstitial lung diseases.

Robert Vassallo1, Jay H Ryu.   

Abstract

Cigarette smoke, a toxic collection of thousands of chemicals generated from combustion of tobacco, is recognized as the primary causative agent of certain diffuse interstitial and bronchiolar lung diseases. Most patients afflicted with these disorders are cigarette smokers, and smoking cessation has been shown to be capable of inducing disease remission and should occupy a pivotal role in the management of all smokers with these diffuse lung diseases. The role of pharmacotherapy with corticosteroids or other immunomodulating agents is not well established but may be considered in patients with progressive forms of smoking-related interstitial lung diseases. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22365253     DOI: 10.1016/j.ccm.2011.11.004

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  22 in total

1.  Smoking-related idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Charlene Fell; Marie-Christine Aubry; Kevin Brown; Thomas Colby; Ulrich Costabel; Teri J Franks; Barry H Gross; David M Hansell; Ella Kazerooni; Dong Soon Kim; Talmadge E King; Masanori Kitachi; David Lynch; Jeff Myers; Sonoko Nagai; Andrew G Nicholson; Venerino Poletti; Ganesh Raghu; Moises Selman; Galen Toews; William Travis; Athol U Wells; Robert Vassallo; Fernando J Martinez
Journal:  Eur Respir J       Date:  2014-07-25       Impact factor: 16.671

Review 2.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

Review 3.  Unusual causes of pneumothorax.

Authors:  Daniel R Ouellette; Scott Parrish; Robert F Browning; J Francis Turner; Konstantinos Zarogoulidis; Ioanna Kougioumtzi; Georgios Dryllis; Ioannis Kioumis; Georgia Pitsiou; Nikolaos Machairiotis; Nikolaos Katsikogiannis; Theodora Tsiouda; Athanasios Madesis; Theodoros Karaiskos; Paul Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  Risk factors for development of acute lung injury, physicians' decision-making roles in critical illness, and prevalence of interstitial lung abnormalities in lung cancer screening populations.

Authors:  Raj D Shah; Paul J Hutchison; Trevor T Nicholson
Journal:  Am J Respir Crit Care Med       Date:  2014-05-15       Impact factor: 21.405

Review 5.  Cardiothoracic manifestations of primary histiocytoses.

Authors:  Daniel Vargas; J Caleb Richards; Daniel Ocazionez; Arlene Sirajuddin; Lorna Browne; Carlos S Restrepo
Journal:  Br J Radiol       Date:  2016-09-26       Impact factor: 3.039

6.  Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.

Authors:  Ibrahim Halil Sahin; Alexander I Geyer; Daniel W Kelly; Eileen Mary O'Reilly
Journal:  Clin Colorectal Cancer       Date:  2015-08-22       Impact factor: 4.481

7.  Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes.

Authors:  Afshin Ebrahimpour; Samana Shrestha; Mark D Bonnen; N Tony Eissa; Ganesh Raghu; Yohannes T Ghebre
Journal:  J Pharmacol Exp Ther       Date:  2018-11-16       Impact factor: 4.030

Review 8.  Effects on health of air pollution: a narrative review.

Authors:  Pier Mannuccio Mannucci; Sergio Harari; Ida Martinelli; Massimo Franchini
Journal:  Intern Emerg Med       Date:  2015-07-02       Impact factor: 3.397

9.  Elevated anti-cyclic citrullinated peptide antibody titer is associated with increased risk for interstitial lung disease.

Authors:  Chase S Correia; Melissa R Briones; Rong Guo; Rochella A Ostrowski
Journal:  Clin Rheumatol       Date:  2019-01-15       Impact factor: 2.980

Review 10.  Diffuse cystic lung diseases.

Authors:  Jay H Ryu; Xinlun Tian; Misbah Baqir; Kaifeng Xu
Journal:  Front Med       Date:  2013-05-11       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.